Categories: News

Signati™ Medical, Inc. Debuts Innovative Bipolar Radio Frequency Sealing Platform at American Urological Association (AUA) Annual Meeting

Providence, RI, May 24, 2022 (GLOBE NEWSWIRE) — Signati™ Medical, Inc. is pleased to announce the unveiling of their innovative Sealed Vasectomy Procedure at this year’s AUA Annual Meeting in New Orleans, LA.

Notably, Signati’s™ technology was featured in a 7-minute abstract and scientific video presented by Dr. Ryan Griggs which was chosen as Best Video of AUA 2022 in the Sexual Dysfunction/Infertility/Andrology section.

The Signati™ Medical proprietary bipolar radio frequency sealing platform provides the ability to monitor impedance, eliminating procedural guesswork and creating effective trans-dermal sealing of the vas deferens. The result is an improved surgical outcome by minimizing damage to the surrounding tissue.

The response to Signati™ Medical’s platform was overwhelmingly positive. Clinicians were excited about the potential impact this product could have on the vasectomy procedure, especially given the lack of innovation in this area over the last twenty years.

About Signati™

Signati™ Medical is a medical device company that endeavors to take vasectomy to a new level of comfort, safety, and speed. A medical device company dedicated to advancing men’s health, Signati™ plans to launch the first innovation in vasectomy in more than 20 years with a procedure that would be fast for physicians and comfortable for patients. The Signati™ procedure, designed to take just minutes, could be done right in the urologist’s office and would offer advantages for patients including easier recovery compared to some current vasectomy techniques.
 To learn more, visit www.signatimed.com.

This product is not approved by the Food and Drug Administration (FDA). These statements and the subject product have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease. The device is not currently being marketed, nor is it available for sale in any country.

CONTACT: William Prentice
President & CEO,
Signati Medical Inc.
128 Dorrance Street
6th Floor
Providence, RI 02903
973-222-2700
william.prentice@signatimed.com


Staff

Recent Posts

Vent Creativity Appoints Paul Abrams as Vice President of Sales to Lead Commercial Growth

NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…

5 hours ago

AEON Clinic Announces Next Generation Medicine Congress 2026 Event: A Global Convergence on Human Longevity in Dubai

AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…

5 hours ago

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

1 day ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

1 day ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

1 day ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

1 day ago